CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
细胞因子在 CAR-T 细胞治疗中的多效性作用
英文原题：The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy.
查看英文原题
The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已经彻底改变了癌症治疗。然而，该疗法的持久缓解率仍然较低，且治疗后存在中重度毒性的风险，需要密切监测。在过去十年中，我们已经了解到细胞因子在介导CAR-T 细胞相关毒性和疗效中发挥重要作用。因此，细胞因子调控已成为改善治疗反应的热门研究领域。尽管许多细胞因子与CAR-T 细胞疗法的关系已被研究，但近期多项研究表明，IFN、IL2、IL4和IL10等细胞因子在CAR-T 细胞反应和毒性中具有矛盾性的作用。在这篇综述中，我们总结了这些细胞因子在免疫治疗中的历史，详细阐述了这些细胞因子在CAR-T 细胞治疗背景下发挥有益或有害作用的具体情境，并讨论了可能决定其多效性的因素。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of cancer.
However, the durable response to this therapy remains low, and there is a risk of moderate-to-severe toxicities following treatment that requires close monitoring. Over the past decade, we have learned that cytokines play an important role in mediating CAR T cell-associated toxicities and efficacy. As such, cytokine modulation has become a popular area of investigation to improve therapeutic responses.
Although the relationship of many cytokines with CAR T-cell therapy has been investigated, several recent studies suggest paradoxical roles for cytokines such as IFN , IL2, IL4, and IL10 in CAR T-cell response and toxicity. In this review, we summarize the history of these cytokines in immunotherapies, detail the contexts in which these cytokines have been beneficial or harmful in the context of CAR T-cell therapy, and discuss factors that may be dictating their pleiotropy.
论文信息
- 作者
- Stewart CM、Siegler EL、Kenderian SS
- 单位
- T Cell Engineering, Mayo Clinic, Rochester, Minnesota.United States
- 文献类型
- 综述
- 期刊
- Cancer immunology research2026 Jan 8
- 原文标识
- PubMed 41324276 · DOI 10.1158/2326-6066.CIR-25-0631
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →